Advertisement
Review article| Volume 23, ISSUE 7, P542-547, November 2001

The role of central histaminergic neuron system as an anticonvulsive mechanism in developing brain

      Abstract

      Experimental and epidemiological studies have indicated that central histaminergic neuron system plays an important role in inhibition of convulsive disorders through histamine H1-receptors, especially in developing period. Histamine H1 antagonists increase the duration of electrically induced convulsions in 21-day-old mice, but not in 42-day-old mice. Epidemiological studies suggested that histamine H1 antagonist may be one of the risk factors in febrile convulsions. In histidinemic patients who were considered to have high brain histamine content, the incidence of convulsions was lower than that of ordinary population.
      The centrally acting histamine H1 antagonists including pyrilamine and ketotifen facilitate the development of amygdaloid kindling in rats, an experimental model of epileptogenic process. On the contrary, epinastine, a histamine H1 antagonist which scarcely enters the brain, shows no facilitation. These findings suggest that the central histaminergic neuron system plays an inhibitory role on the seizure development through central histamine H1-receptors.
      Recently, three cases has been reported in which West syndrome developed 8–10 days after ketotifen or oxatomide administration. Considering experimental and clinical studies, histamine H1 antagonists may be associated with West syndrome and may be hazardous to infants. Further careful experimental and clinical studies will be required to elucidate the relationships between West syndrome and central histaminergic neuron system.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Green J.P.
        Histamine.
        in: Lajtha A. Handbook of neurochemistry. Plenum Press, London1970: 221-235
        • Snyder S.H.
        • Taylor K.M.
        Isotopic micorassay of histamine histidine decarboxylase and histmaine methyltransferase in brain tissue.
        J Neurochem. 1972; 19: 1343-1358
        • Watanabe T.
        • Taguchi Y.
        • Hayashi H.
        Distribution of the histaminergic neuron system in the central nervous system of rats: a fluorescent immunohistochemical analysis with histidine decarboxylase as a marker.
        Brain Res. 1984; 295: 13-25
        • Pannula P.
        • Yang H.Y.T.
        • Costa E.
        Histamine-containing neurons in the rat hypothalamus.
        Proc Natl Acad Sci USA. 1984; 81: 2572-2576
        • Schwartz J.C.
        • Arrang J.M.
        • Garbarg M.
        • Pallard H.
        • Rust M.
        Histaminergic transmission in the mammalian brain.
        Physiol Rev. 1991; 71: 1-51
        • Wada H.
        • Inagaki N.
        • Yamatodani A.
        Is the histaminergic neuron system a regulatory center for whole brain activity?.
        Trends Neurosci. 1991; 14: 415-419
        • Churchill J.A.
        • Gammon G.D.
        The effect of antihistaminic drugs on convulsive seizures.
        J Am Med Assoc. 1949; 141: 18-21
        • Wyngaarden J.B.
        • Seevers M.H.
        The toxic effects of antihistaminic drugs.
        J Am Med Assoc. 1951; 145: 277-283
        • Schwartz J.F.
        • Patterson J.H.
        Toxic encephalopathy related to antihistamine-barbiturate antiemetic medication.
        Am J Dis Child. 1978; 132: 37-39
        • Shishido S.
        • Oishi R.
        • Saeki K.
        In vivo effects of some histamine H1-receptor antagonists on monoamine metabolism in the mouse brain.
        Naunyn Schmiedebergs Arch Pharmacol. 1991; 343: 185-189
        • Yokoyama H.
        • Iinuma K.
        • Yanai K.
        • Watanabe T.
        • Sakurai E.
        • Onodera K.
        Proconvulsant effect of ketotifen, a histamine H1 antagonist, confirmed by the use of d-chlorpheniramine with monitoring electroencephalography.
        Methods Find Exp Clin Pharmacol. 1993; 15: 183-188
        • Yamatogi Y.
        Seizures and classification of epilepsies.
        in: Matsutomo R. Treatment of intractable epilepsies. Budosha, Tokyo1991: 33 (in Japanese)
        • Gerald M.C.
        • Richter N.A.
        Studies on the effects of histaminergic agents on seizure susceptibility in mice.
        Psychopharmacologia. 1976; 46: 277-282
        • Fairbairn S.
        • Sturman G.
        The influence of central histaminergic modification on the susceptibility of mice to chemically-induced seizures.
        Br J Pharmacol. 1989; 97: 317
        • Yokoyama H.
        • Onodera K.
        • Iinuma K.
        • Watanabe T.
        Proconvulsive effects of histamine H1-antagonists on electrically-induced seizure in developing mice.
        Psychopharmacology. 1993; 112: 199-203
        • Ghadini H.
        • Partington M.W.
        • Hunter A.
        A familial disturbance of histidine metabolism.
        N Engl J Med. 1961; 265: 211-224
        • Tanabe M.
        • Sakura N.
        Hyperhistaminemia in patients with histidinemia due to increased decarboxylation of histidine.
        Clin Chim Acta. 1989; 186: 11-17
        • Taylor R.G.
        • Levy H.L.
        • McInnes R.R.
        Histidase and histidinemia Clinical and molecular considerations.
        Mol Biol Med. 1991; 8: 101-116
        • Imamura I.
        • Watanabe T.
        • Hase Y.
        • Sakamoto Y.
        • Fukuda Y.
        • Yamamoto H.
        • et al.
        Histamine metabolism in patients with histidinemia: determination of urinary levels of histamine, N tau-methylhistamine, imidazole acetic acid, and its conjugates.
        J Biochem (Tokyo). 1984; 96: 1925-1929
        • Wadman S.K.
        • Van Sprang F.J.
        • Van Stekelenburg G.J.
        • De Bree P.K.
        Three new cases of histidinemia. Clinical and biochemical data.
        Z Gesamte Inn Med. 1966; 21: 485-492
        • Aoki K.
        Revision of the nutritional management of histidinemia.
        Shouni-Igaku (Tokyo). 1989; 22 (in Japanese): 265-277
        • Galland M.C.
        • Griguer Y.
        • Morange-Sala S.
        • Jean-Pastor M.J.
        • Rodor F.
        • Jouglard J.
        Convulsions fébriles: faut-il contre-indiquer certains médicaments?.
        Therapie. 1992; 47: 409-414
        • Yokoyama H.
        • Iinuma K.
        Histaminergic neurons and epilepsy.
        Methods Find Exp Clin Pharmacol. 1996; 18: 181-186
        • Kiviranta T.
        • Tuomisto L.
        • Airaksinen E.M.
        Histamine in cerebrospinal fluid of children with febrile convulsions.
        Epilepsia. 1995; 36: 276-280
        • Iinuma K.
        • Yokoyama H.
        • Otsuki T.
        • Yanai K.
        • Watanabe T.
        • Ido T.
        • et al.
        Histamine H1 receptors in complex partial seizures.
        Lancet. 1993; 341: 238
        • Toyota H.
        • Ito C.
        • Ohsawa M.
        • Sakurai E.
        • Sato M.
        • Watanabe T.
        Decreased central histamine in the amygdaloid kindling rats.
        Brain Res. 1998; 802: 241-246
        • Yokoyama H.
        • Sato M.
        • Iinuma K.
        • Onodera K.
        • Watanabe T.
        Centrally acting histamine H1 antagonists promote the development of amygdala kindling in rats.
        Neurosci Lett. 1996; 217: 194-196
        • Kamei C.
        • Ishizawa K.
        • Kakinoki H.
        • Fukunaga M.
        Histaminergic mechanisms in amygdaloid-kindled seizures in rats.
        Epilepsy Res. 1998; 30: 187-194
        • McDonald J.W.
        • Johnston M.V.
        • Young A.B.
        Differential ontogenic development of three receptors comprising the NMDA receptor/channel complex in the rat hippocampus.
        Exp Neurol. 1990; 110: 237-247
        • Insel T.R.
        • Miller L.P.
        • Gelhard R.E.
        The ontogeny of excitatory amino acid receptors in the rat forebrain-I N-methyl-d-aspartate and quisqualate receptors.
        Neuroscience. 1990; 35: 31-43
        • Caboche J.
        • Mitrovic N.
        • Le Saux F.
        • Besson M.J.
        • Sauter A.
        • Maurin Y.
        Postnatal evolution of the γ-aminobutyric acid/benzodiazepine receptor complex in a model of inherited epilepsy: the quaking mouse.
        J Neurochem. 1989; 52: 419-427
        • Poulter M.O.
        • Brown L.A.
        • Tynan S.
        • Willick G.
        • William R.
        • McIntyre D.C.
        Differential expression of alpha1, alpha2, alpha3, and alpha5 GABAA receptor subunits in seizure-prone and seizure-resistant rat models of temporal lobe epilepsy.
        J Neurosci. 1999; 19: 4654-4661
        • Tuomisto L.
        • Pannula P.
        Development of histaminergic neurons.
        in: Watanabe T. Wada H. Histaminergic neurons: morphology and function. CRC Press, Boca Raton1991: 177-194
        • Lintunen M.
        • Sallmen T.
        • Karlstedt K.
        • Fukui H.
        • Eriksson K.S.
        • Panula P.
        Postnatal expression of H1-receptor mRNA in the rat brain: correlation to l-histidine decarboxylase expression and local upregulation in limbic seizures.
        Eur J Neurosci. 1998; 10: 2287-2301
        • Yasuhara A.
        • Ochi A.
        • Harada Y.
        • Kobayashi Y.
        Infantile spasms associated with a histamine H1 antagonist.
        Neuropediatrics. 1998; 29: 320-321
        • Yamashita Y.
        • Seki Y.
        • Isagaki T.
        • Iemura A.
        • Fukui R.
        • Matsuishi T.
        West syndrome possibly induced by an administration of oxatomide.
        in: Fukuyama Y. Abstracts of International Symposium on the West Syndrome and Other Infantile Epileptic Encephalopathies, Tokyo, February 9–11, 2001. 2001: 64